Pre-Made Pabinafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with iduronate-2-sulfatase: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 for drug discovery and mechanism of action (MOA) research

Pre-Made Pabinafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with iduronate-2-sulfatase: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enzyme replacement therapy (ERT) improves somatic manifestations in mucopolysaccharidoses (MPS). However, because intravenously administered enzymes cannot cross the blood–brain barrier (BBB), ERT is ineffective against the progressive neurodegeneration and resultant severe central nervous system (CNS) symptoms observed in patients with neuronopathic MPS. Pabinafusp alfa is a human iduronate-2-sulfatase fused with a BBB-crossing anti-transferrin receptor (Tfr) antibody, which successfully deliver across the BBB into the CNS by way of TfR-mediated transcytosis and decrease heparan sulfate (HS) accumulations in the brain. pabinafusp alfa is effective against both the somatic and CNS symptoms of patients with MPS-II.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-943-1mg	1mg	3090
GMP-Bios-INN-943-10mg	10mg	Inquiry
GMP-Bios-INN-943-100mg	100mg	Inquiry
GMP-Bios-INN-943-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Pabinafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with iduronate-2-sulfatase: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90
INN Name	Pabinafusp Alfa
Target	TFRC
Format	Fusion Protein
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	JCR Pharmaceuticals Co., Ltd (Ashiya Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0